COVID-19

Trademark

Unclaimed Request correction

COVID-19 is an infectious respiratory disease caused by the coronavirus SARS-CoV-2 and first identified in late 2019.

Last updated October 7, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2, commonly abbreviated SARS-CoV-2. The disease was first recognized during an outbreak in Wuhan, China, in late 2019. It subsequently spread internationally and became the defining global public-health crisis of 2020 and much of the early 2020s. Because COVID-19 is a disease rather than a corporation, product, or commercial brand, it has no founder, owner, headquarters, parent company, listed shares, or conventional operating markets. The supplied country field of France does not describe the subject accurately: COVID-19 is global in scope, although France was among the countries substantially affected by the pandemic. The illness primarily affects the respiratory system, but its clinical presentation ranges from asymptomatic infection to severe pneumonia, respiratory failure, cardiovascular complications, neurological effects, multisystem inflammatory conditions, and death. Risk has varied according to age, underlying health conditions, immunity, viral variant, vaccination status, and access to medical care. A subset of people experience persistent symptoms after the acute infection, commonly referred to as long COVID or post-COVID-19 condition. Public-health responses included diagnostic testing, genomic surveillance, isolation of cases, contact tracing, masking, improvements in ventilation, restrictions on gatherings and travel, temporary closure of schools and businesses, vaccination programmes, and treatment with antiviral or other supportive medicines. The intensity and timing of these measures differed by country and changed as evidence, health-system capacity, vaccines, treatments, and circulating variants evolved. Vaccines substantially altered the risk profile of severe disease, hospitalization, and death, while successive variants changed transmissibility and the degree of immune escape. COVID-19 also became a major subject of public communication, social marketing, advertising, and institutional campaigning. Governments, hospitals, universities, charities, technology companies, media organizations, and consumer brands used messages encouraging people to stay home when ill, reduce contacts, wear masks where appropriate, seek testing, and receive vaccination. Some commercial campaigns focused on solidarity and remote connection, while public-health campaigns emphasized prevention and risk reduction. The communications environment was also marked by misinformation, politicization, unequal access to reliable information, and public fatigue. The pandemic produced extensive economic and social effects. It disrupted travel, hospitality, retail, manufacturing, education, employment, and supply chains, while accelerating remote work, telemedicine, e-commerce, digital payments, and online media consumption. Mergers and acquisitions initially slowed sharply amid uncertainty and financing constraints, while technology, healthcare, biotechnology, and digitally enabled businesses often proved more resilient than sectors dependent on physical interaction. The disease remains a continuing public-health concern rather than a discontinued phenomenon, with ongoing vaccination, surveillance, clinical research, and management of periodic waves.

History

COVID-19 emerged as a newly recognized human disease in late 2019 during an outbreak in Wuhan, China. The causative virus was initially identified as a novel coronavirus and was later named SARS-CoV-2 by the International Committee on Taxonomy of Viruses. The World Health Organization named the disease COVID-19 in February 2020. Early investigations focused on the clinical syndrome, the virus's genetic characteristics, patterns of transmission, and possible animal origins. The precise origins and early transmission history have remained the subject of continuing scientific and political investigation. During January and February 2020, cases were reported outside China and international public-health agencies expanded surveillance and preparedness efforts. The WHO declared a public health emergency of international concern on 30 January 2020 and characterized the outbreak as a pandemic on 11 March 2020. Countries introduced measures including testing, isolation, contact tracing, border controls, restrictions on large gatherings, school closures, stay-at-home orders, and requirements or recommendations concerning face coverings. These interventions sought to slow transmission, prevent hospitals from becoming overwhelmed, and protect people at elevated risk. The first pandemic year was marked by severe uncertainty. Diagnostic capacity was expanded rapidly, but testing access varied widely. Governments and health authorities revised advice as evidence developed concerning asymptomatic transmission, airborne or aerosol spread, ventilation, masks, immunity, and the duration of protection after infection. Social and economic disruption was extensive: travel and tourism contracted, supply chains were interrupted, unemployment increased in many regions, and education moved online for large populations. At the same time, remote-work tools, telemedicine, online retail, digital entertainment, and home-delivery services expanded. Research and development efforts produced vaccines, diagnostic tests, and treatments at unprecedented speed. Several vaccine platforms, including messenger RNA, viral-vector, protein-based, and inactivated-virus approaches, entered large-scale deployment from late 2020 onward. Vaccination campaigns were accompanied by debates over prioritization, mandates, safety monitoring, intellectual property, procurement, distribution, and global equity. Antiviral medicines and other clinical interventions improved the ability to manage some infections, although outcomes continued to depend on individual risk and healthcare access. The virus evolved through multiple waves and variants. Variants with increased transmissibility or immune escape changed the effectiveness of particular interventions and required updated vaccines, public-health guidance, and surveillance. The Omicron lineage and its descendants produced major waves beginning in late 2021, while population immunity from vaccination and previous infection generally altered the relationship between infection, severe disease, and mortality. Health systems nevertheless continued to face periodic pressure, and long COVID became an important area of clinical research and patient advocacy. COVID-19 communications became a major field of public-health and commercial campaigning. Messages promoted staying home during periods of high transmission, masking, vaccination, testing, ventilation, and consideration for vulnerable people. Randomized research found that targeted social-media messages delivered by healthcare professionals could reduce holiday travel and subsequent infections. Universities and community organizations developed branded vaccination and safety campaigns, while consumer companies adapted advertising to emphasize solidarity, home life, digital connection, or support for frontline workers. The period also generated misinformation, conspiracy theories, disputes over policy, and concern about the commercial exploitation of fear and uncertainty. On 5 May 2023, the WHO determined that COVID-19 no longer met the criteria for a public health emergency of international concern. This did not mean that the disease had disappeared. COVID-19 continued to circulate, with ongoing waves, vaccination updates, clinical treatment, surveillance, and research. The post-emergency phase has focused on integrating COVID-19 into continuing respiratory-disease surveillance while addressing excess mortality, delayed healthcare, educational disruption, mental-health effects, economic scarring, health inequalities, and persistent symptoms after infection.

2023
Global health emergency ends
[3]Statement on the fifteenth meeting of the International Health Regulations Emergency Committee regarding the COVID-19 pandemicwho.int
The WHO ended the COVID-19 public health emergency of international concern while retaining long-term public-health recommendations.
2021
Omicron identified
[10]Omicron identifiedwho.int
The WHO designated Omicron as a variant of concern after its identification and early evidence of substantial transmissibility and immune-evasion characteristics.
2020
Disease named COVID-19
[2]Naming the coronavirus disease (COVID-19) and the virus that causes itwho.int
The World Health Organization announced COVID-19 as the official name for the disease caused by the newly identified coronavirus.
2020
Pandemic characterization
[8]Pandemic characterizationwho.int
The WHO characterized COVID-19 as a pandemic as sustained transmission expanded internationally.
2020
Initial vaccine deployments
[9]Initial vaccine deploymentswho.int
The first COVID-19 vaccines received regulatory or emergency-use authorizations and began to be administered in several countries.
2019
First recognized outbreak
[7]First recognized outbreakwho.int
A cluster of unexplained respiratory illnesses was identified in Wuhan, China, later linked to the novel coronavirus SARS-CoV-2.

Products and positioning

Not applicable as a commercial brand; COVID-19 is a disease and public-health subject.

Controversies

2021
Vaccine-access and distribution inequality
The global vaccine rollout generated sustained criticism over unequal access between countries and populations, including procurement power, manufacturing concentration, intellectual-property constraints, and delivery capacity.
Source
2020
Misinformation and politicization during the pandemic
COVID-19 was accompanied by widespread false or misleading claims about transmission, prevention, treatments, vaccines, and public-health policy. The resulting information disorder created challenges for health authorities, platforms, journalists, and the public.
Source
2020
Origins and early-response controversy
The origins of SARS-CoV-2 and the adequacy and timing of early information-sharing and response measures became subjects of scientific, governmental, and political dispute. Evidence and conclusions have evolved as investigations and data review continued.
Source

2021AUBe Vaccinated
Lebanon
The American University of Beirut developed a co-designed social-marketing campaign using a campaign identity, digital communications, booking tools, and on-campus materials to encourage vaccination among students, faculty, staff, and dependents.
Outcome. The case study described the campaign as an evidence-based effort to improve vaccine availability, access, and uptake within the university community.
Source
2020Stay Home Protect the NHS Save Lives
United Kingdom
A public-health campaign associated with the UK National Health Service encouraged people to remain at home, reduce transmission, and protect hospitals and health workers during the first wave.
Source
2020Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections
United States
A randomized campaign used short videos recorded by doctors and nurses to encourage people to stay home during Thanksgiving and Christmas. The study reported lower subsequent infections in intervention counties than in control counties.
Outcome. The intervention was associated with a reported 3.5% reduction in infections during the measured post-holiday period.
Source
2020Stay Home
Global
Airbnb promoted staying home and offered online experiences as travel restrictions and physical-distancing measures limited in-person tourism.
Source
2020Home Team
Global
Adidas encouraged people to remain active during lockdowns through at-home workouts, athlete participation, and digital fitness content.
Source
2020Protect the Pack
United States
Northeastern University used campus signage, a mural, transit placements, and a reusable communications toolkit to explain safety protocols and support reopening during the pandemic.
Outcome. The campaign was recognized for integrating public-health messaging into the university environment and for reporting positive community metrics.
Source

Brand decisions

2023
Transition from emergency response to long-term managementStrategy
Background
Global health systems had accumulated substantial immunity and response capacity, although SARS-CoV-2 continued to circulate and cause illness.
Action taken
The WHO ended the public health emergency of international concern and urged countries to continue integrating COVID-19 surveillance, vaccination, and care into broader health systems.
Aftermath
COVID-19 entered a continuing management phase rather than ending as a disease; periodic waves and post-infection illness remained important concerns.
Source
2020
Declaration of a public health emergency of international concernOther
Background
International spread of the newly recognized disease created a need for coordinated surveillance, preparedness, and response.
Action taken
The WHO declared COVID-19 a public health emergency of international concern on 30 January 2020.
Aftermath
The declaration supported international coordination and helped frame the outbreak as a global public-health threat.
Source
2020
Pandemic characterizationOther
Background
Transmission had expanded across countries and regions, with sustained community spread and major risks to health systems.
Action taken
The WHO characterized COVID-19 as a pandemic on 11 March 2020.
Aftermath
Governments intensified public-health measures, including testing, distancing, travel controls, and restrictions on gatherings.
Source
2020
Emergency deployment of COVID-19 vaccinesProduct launch
Background
Rapid vaccine development produced multiple candidates while severe disease and healthcare pressure remained high.
Action taken
Regulators and public-health authorities authorized the first vaccines for emergency or conditional use, followed by phased vaccination programmes.
Aftermath
Vaccination became a central tool for reducing severe disease and mortality, while questions about safety, access, mandates, and variants continued.
Source

Recent events

2023
WHO ends COVID-19 global health emergency[3]Statement on the fifteenth meeting of the International Health Regulations Emergency Committee regarding the COVID-19 pandemicwho.int
Regulation · Other
WHO announced that COVID-19 no longer constituted a public health emergency of international concern, while emphasizing that the disease remained an ongoing global health issue.
2020
WHO declares COVID-19 a public health emergency of international concern[7]First recognized outbreakwho.int
Regulation · Other
The World Health Organization characterized the international outbreak as a public health emergency of international concern, supporting coordinated global surveillance and response.
2020
WHO characterizes COVID-19 as a pandemic[8]Pandemic characterizationwho.int
Other
The World Health Organization described COVID-19 as a pandemic as transmission expanded across multiple regions and countries.

Sources15 sources

Cite this profile: Cite the canonical profile. /brand-wiki/covid-19 · Editorial policy · How profiles are compiled